Heron Therapeutics | HRTX - Ebitda


Heron Therapeutics reported $-3.88M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
ALKERMES USD 139.22M 58.96M Jun/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amarin USD 12.54M 28.57M Jun/2025
ANI Pharmaceuticals USD 71.6M 6.69M Jun/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
Eisai JPY 34.15B 34.48B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -148.3M 165.88M Mar/2026
Ligand Pharmaceuticals USD -14.3M 81.08M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 48.67M 8.43M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Veracyte USD 43.96M 1.16M Jun/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026